Nymox Pharmaceutical annual current ratio
2017
2018
2019
2020
2021
2022
2023
2024
Nymox Pharmaceutical Current Ratio Growth & History (NYMXF)
Nymox Pharmaceutical's current ratio was 0.09 for fiscal 2024.
View full Nymox Pharmaceutical company overviewNymox Pharmaceutical annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | 0.09 | −0.08 | −46.56% |
| 2023 | 2023-12-31 | 0.16 | −0.53 | −76.22% |
| 2022 | 2022-12-31 | 0.69 | 0.11 | +19.10% |
| 2021 | 2021-12-31 | 0.58 | −1.40 | −70.69% |
| 2020 | 2020-12-31 | 1.98 | −0.63 | −24.22% |
| 2019 | 2019-12-31 | 2.61 | −4.86 | −65.02% |
| 2018 | 2018-12-31 | 7.47 | 7.04 | +1634.11% |
| 2017 | 2017-12-31 | 0.43 | — | — |
Nymox Pharmaceutical quarterly current ratio
Q4.17
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q3.24
Q4.24
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2024 | 2024-12-31 | 0.09 | −0.08 | −46.56% |
| Q3 2024 | 2024-09-30 | 0.09 | −0.16 | −64.61% |
| Q4 2023 | 2023-12-31 | 0.16 | −0.53 | −76.22% |
| Q3 2023 | 2023-09-30 | 0.25 | −0.98 | −79.40% |
| Q2 2023 | 2023-06-30 | 0.07 | −1.84 | −96.44% |
| Q1 2023 | 2023-03-31 | 0.19 | −0.16 | −45.02% |
| Q4 2022 | 2022-12-31 | 0.69 | 0.11 | +19.10% |
| Q3 2022 | 2022-09-30 | 1.24 | −0.63 | −33.60% |
| Q2 2022 | 2022-06-30 | 1.91 | −1.91 | −50.05% |
| Q1 2022 | 2022-03-31 | 0.35 | −0.59 | −62.42% |
| Q4 2021 | 2021-12-31 | 0.58 | −1.40 | −70.69% |
| Q3 2021 | 2021-09-30 | 1.86 | −1.11 | −37.39% |
| Q2 2021 | 2021-06-30 | 3.83 | 3.39 | +770.88% |
| Q1 2021 | 2021-03-31 | 0.94 | −0.80 | −45.84% |
| Q4 2020 | 2020-12-31 | 1.98 | −0.63 | −24.22% |
| Q3 2020 | 2020-09-30 | 2.97 | −1.37 | −31.52% |
| Q2 2020 | 2020-06-30 | 0.44 | −4.94 | −91.83% |
| Q1 2020 | 2020-03-31 | 1.74 | −6.30 | −78.41% |
| Q4 2019 | 2019-12-31 | 2.61 | −4.86 | −65.02% |
| Q3 2019 | 2019-09-30 | 4.34 | — | — |
| Q2 2019 | 2019-06-30 | 5.38 | — | — |
| Q1 2019 | 2019-03-31 | 8.04 | — | — |
| Q4 2018 | 2018-12-31 | 7.47 | 7.04 | +1634.11% |
| Q4 2017 | 2017-12-31 | 0.43 | — | — |
Nymox Pharmaceutical current ratio trends
Over the last five fiscal years, Nymox Pharmaceutical's current ratio decreased from 2.61 to 0.09, a change of −2.53. The latest reported quarter, Q4 2024, shows 0.09.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nymox Pharmaceutical source filings ↗